(Q45205291)

10 December 2017

title

Alzheimer CSF biomarkers in routine clinical setting (English)

1 reference

10 December 2017

0 references

0 references

F Tabaraud

1

1 reference

10 December 2017

J P Leman

2

1 reference

10 December 2017

A M Milor

3

1 reference

10 December 2017

J M Roussie

4

1 reference

10 December 2017

G Barrière

5

1 reference

10 December 2017

M Tartary

6

1 reference

10 December 2017

F Boutros-Toni

7

1 reference

10 December 2017

M Rigaud

8

1 reference

10 December 2017

language of work or name

English

0 references

publication date

28 September 2011

1 reference

Acta Neurologica Scandinavica

10 December 2017

published in

1 reference

10 December 2017

volume

125

1 reference

10 December 2017

issue

6

1 reference

10 December 2017

page(s)

416-423

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2011.01592.X

10 December 2017

1 reference

APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2011.01592.X

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2011.01592.X

Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2011.01592.X

EFNS guidelines for the diagnosis and management of Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2011.01592.X

Revising the definition of Alzheimer's disease: a new lexicon.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2011.01592.X

Mild cognitive impairment: clinical characterization and outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2011.01592.X

CSF markers for incipient Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2011.01592.X

Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2011.01592.X

CSF phosphorylated tau in the diagnosis and prognosis of mild cognitive impairment and Alzheimer's disease: a meta-analysis of 51 studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2011.01592.X

Improved discrimination of AD patients using beta-amyloid(1-42) and tau levels in CSF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2011.01592.X

Cerebrospinal fluid tau and beta-amyloid in Alzheimer patients, disease controls and an age-matched random sample.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2011.01592.X

Analytical performance and clinical utility of the INNOTEST PHOSPHO-TAU181P assay for discrimination between Alzheimer's disease and dementia with Lewy bodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2011.01592.X

Diagnosing prodromal Alzheimer's disease: role of CSF biochemical markers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2011.01592.X

Cerebrospinal fluid biomarkers and prediction of conversion in patients with mild cognitive impairment: 4-year follow-up in a routine clinical setting.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2011.01592.X

Baseline CSF p-tau levels independently predict progression of hippocampal atrophy in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2011.01592.X

Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2011.01592.X

CSF biomarkers predict a more malignant outcome in Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2011.01592.X

Diagnostic impact of CSF biomarkers in a local hospital memory clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2011.01592.X

Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2011.01592.X

CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2011.01592.X

Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2011.01592.X

CSF phosporylated TAU protein levels correlate with cerebral glucose metabolism assessed with PET in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2011.01592.X

Amyloid beta peptide ratio 42/40 but not A beta 42 correlates with phospho-Tau in patients with low- and high-CSF A beta 40 load.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2011.01592.X

Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2011.01592.X

Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2011.01592.X

Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2011.01592.X

Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2011.01592.X

Combined CSF tau, p-tau181 and amyloid-beta 38/40/42 for diagnosing Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2011.01592.X

CSF biomarkers for mild cognitive impairment and early Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2011.01592.X

Mixed brain pathologies account for most dementia cases in community-dwelling older persons

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2011.01592.X

In vivo amyloid imaging in autopsy-confirmed Parkinson disease with dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2011.01592.X

10.1111/J.1600-0404.2011.01592.X

21 January 2018

Identifiers

DOI

1 reference

10 December 2017

1 reference